Investcub
2021-11-22
Happy to see competition is heating up!!!
Novartis plans new sales approach for cholesterol lowering drug - WSJ
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":875060514,"tweetId":"875060514","gmtCreate":1637588833510,"gmtModify":1637588855672,"author":{"id":3584582153384625,"idStr":"3584582153384625","authorId":3584582153384625,"authorIdStr":"3584582153384625","name":"Investcub","avatar":"https://static.tigerbbs.com/b34bc19b19d991e55d86b53b1e4a44ff","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":39,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Happy to see competition is heating up!!!</p></body></html>","htmlText":"<html><head></head><body><p>Happy to see competition is heating up!!!</p></body></html>","text":"Happy to see competition is heating up!!!","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/875060514","repostId":1135443897,"repostType":4,"repost":{"id":"1135443897","kind":"news","pubTimestamp":1637584143,"share":"https://www.laohu8.com/m/news/1135443897?lang=&edition=full","pubTime":"2021-11-22 20:29","market":"us","language":"en","title":"Novartis plans new sales approach for cholesterol lowering drug - WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=1135443897","media":"seekingalpha","summary":"In a bid to take on well-established rivals, Novartis(NYSE:NVS)is formulating a non-traditional sale","content":"<p>In a bid to take on well-established rivals, Novartis(NYSE:NVS)is formulating a non-traditional sales strategy to promote the company’s cholesterol-busting therapy Leqvio, <i>TheWall Street Journal</i> reports.</p>\n<p>Unlike a promotional strategy reliant on sales representatives, the Swiss pharma giant plans to sell Leqvio targeting 200 hospital systems across the nation.</p>\n<p>Through the so-called population health approach, the company expects the health care systems through electronic health records to assist it in identifying the patients who could qualify for the drug after failing to control their cholesterol with current therapies.</p>\n<p>For decades, patients took statins to control the type of cholesterol, low-density lipoprotein, or LDL targeted by Leqvio.</p>\n<p>However, the twice-yearly injection is said to be more powerful than statins and competes against Repatha from Amgen(NASDAQ:AMGN)and Praluent from Sanofi(NASDAQ:SNY)and Regeneron(NASDAQ:REGN), two other drugs with a similar mechanism of action to Leqvio.</p>\n<p>With Repatha and Praluent requiring self-injection every two or four weeks, Novartis (NVS) expects Leqvio will have the edge with twice-yearly dosing.</p>\n<p>In late 2020, Leqvio, also called inclisiran, was approved in Europe.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis plans new sales approach for cholesterol lowering drug - WSJ</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis plans new sales approach for cholesterol lowering drug - WSJ\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-22 20:29 GMT+8 <a href=https://seekingalpha.com/news/3773170-novartis-plans-new-sales-approach-for-cholesterol-lowering-drug-wsj><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In a bid to take on well-established rivals, Novartis(NYSE:NVS)is formulating a non-traditional sales strategy to promote the company’s cholesterol-busting therapy Leqvio, TheWall Street Journal ...</p>\n\n<a href=\"https://seekingalpha.com/news/3773170-novartis-plans-new-sales-approach-for-cholesterol-lowering-drug-wsj\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVS":"诺华"},"source_url":"https://seekingalpha.com/news/3773170-novartis-plans-new-sales-approach-for-cholesterol-lowering-drug-wsj","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1135443897","content_text":"In a bid to take on well-established rivals, Novartis(NYSE:NVS)is formulating a non-traditional sales strategy to promote the company’s cholesterol-busting therapy Leqvio, TheWall Street Journal reports.\nUnlike a promotional strategy reliant on sales representatives, the Swiss pharma giant plans to sell Leqvio targeting 200 hospital systems across the nation.\nThrough the so-called population health approach, the company expects the health care systems through electronic health records to assist it in identifying the patients who could qualify for the drug after failing to control their cholesterol with current therapies.\nFor decades, patients took statins to control the type of cholesterol, low-density lipoprotein, or LDL targeted by Leqvio.\nHowever, the twice-yearly injection is said to be more powerful than statins and competes against Repatha from Amgen(NASDAQ:AMGN)and Praluent from Sanofi(NASDAQ:SNY)and Regeneron(NASDAQ:REGN), two other drugs with a similar mechanism of action to Leqvio.\nWith Repatha and Praluent requiring self-injection every two or four weeks, Novartis (NVS) expects Leqvio will have the edge with twice-yearly dosing.\nIn late 2020, Leqvio, also called inclisiran, was approved in Europe.","news_type":1},"isVote":1,"tweetType":1,"viewCount":792,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":35,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/875060514"}
精彩评论